DongKook Pharmaceutical동국제약
086450 · KOSDAQ · ₩086450 · 동국제약
₩23,450▼ ₩450 (1.88%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 55.3% | 54.1% | 55.1% | 56.2% | 57.4% | 58.9% |
| Operating margin | 10.5% | 10.4% | 9.9% | 9.1% | 11.0% | 10.6% |
| Net margin | 7.8% | 7.1% | 7.5% | 6.5% | 8.0% | 8.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +5.7% | +14.1% | +11.1% | +10.5% | +11.4% | — |
| Operating income growth | +6.2% | +20.1% | +20.3% | −8.0% | +14.9% | — |
| Net income growth | +15.6% | +7.8% | +29.8% | −10.8% | +5.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 11.2% | 10.4% | 10.7% | 9.0% | 11.1% | 11.1% |
| Return on assets | 6.7% | 7.3% | 7.0% | 6.1% | 7.2% | 7.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 40.1% | 39.2% | 40.4% | 45.7% | 44.7% | 55.7% |
| Net debt to equity | −14.0% | −15.4% | −13.3% | −3.0% | −1.4% | 2.6% |
| Current ratio | 204.7% | 211.4% | 202.0% | 181.4% | 194.1% | 173.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: DongKook Pharmaceutical / 동국제약 / 086450 / KRX:086450
Source: KRX statistical information